Researchers from the Clinic for Special Children have developed a drug delivery catheter system that could reach a larger population of patients receive Biogen’s Spinraza treatment.
Tjoapack and Veratrak partnered to establish the use of blockchain technology across the pharmaceutical industry for the first time in a GxP environment.
IIVS is collaborating with global laboratories to validate an improved skin sensitization reactivity method to meet toxicology and regulatory requirements.
Deloitte’s acquisition of QSpace expands its IT quality and compliance solutions offering for life sciences firms, including contract research and manufacturing organizations.
Science Exchange has partnered with Taconic Biosciences, a supplier of genetically engineered rodent models to offer access to Taconic’s portfolio including the company’s Easi-CRISPR technology.
Glaukos Pharmaceutical, an ophthalmic medical technology and pharmaceutical company, and D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company, have announced an agreement.
Genetic testing could potentially transform the way clinical trials are conducted – but for the patient, the role of the genetic counselor is a key component of this process.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
The US FDA has rejected Mallinckrodt Pharmaceuticals’ investigational candidate, stannsoporfin, intended for the treatment of newborns at risk of jaundice.
Preparations for an “unlikely” ‘no deal’ Brexit are underway in the UK, with the government instructing pharmaceutical companies to build their medicine reserves before March 2019.
Harvard Medical School and Brigham Women’s Hospital have selected the Aetion Evidence Platform to further support the REPEAT program and the demand for RWE.
Fusion Antibodies revenue grew 41% in FY2018, and while “pop up consultants” have created new competition, the CRO is differentiating itself by investing in its services and focusing on quality.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
The Coalition for Epidemic Preparedness Innovations announced a collaboration with IDT Biologika for MERS vaccine development in which IDT will receive up to $36m.
Altasciences is set to acquire SNBL in a deal that looks to bridge the gap between preclinical and proof of concept studies – and provide an average of 25% time savings, says CEO.
An alliance between Kinetiq and Halley Consulting group aims to provide new services to the companies’ clients, from compensation analysis to technology compliance solutions.
Alpha Genesis is exploring blockchain technology applications in its primate research activities – the use of which aims to boost transparency and traceability across several areas of the business.
Boehringer Ingelheim’s China-based CDMO is providing clinical trial materials for CANbridge Life Sciences' Phase Ib/III study of its drug candidate intended to treat esophageal cancer.
The US FDA has granted expiration date extensions for specific lots of Mylan’s EpiPen auto-injectors, as manufacturer Pfizer works to stabilise supply.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.
Sygnature Discovery is adding a new facility at Alderley Park in Cheshire, UK in response to an increasing demand for outsourced preclinical research services.
Industry executives are welcoming the FDA’s draft guidance on expansion cohort use in first-in-human clinical trials – the increasing use of which is evidence of a changing drug development paradigm, says CRO.
Syneos Health has acquired the UK-based advisory firm Kinapse in a deal that will double its consulting footprint in Europe and further strengthen its commercial offerings – one company's fastest-growing lines of business, says CEO.